Insights
Search Results
Client Highlights
8.13.26
Firm Advises Khartis Therapeutics on Patent Matters Related to $50 Million Series B
On August 13, 2026, Khartis Therapeutics, a biotechnology company developing both first- and best-in-class oral small molecule medicines for immunological and chronic diseases, announced that it has raised $50 million in Series B financing. The round was led by Forge Life Science Partners, with participation from Longwood Fund and Alexandria Venture Investments, alongside existing investors Foresite Capital, Lilly Asia Ventures, and Nextech Invest, bringing total capital raised to $95 million. Wilson Sonsini Goodrich & Rosati advised Khartis on patent matters related to the transaction and has served as patent counsel for the company since its inception in 2024.
Client Highlights
8.11.26
Firm Advises Braveheart Bio on Patent Matters Related to $382.5 Million IPO
On August 5, 2026, Braveheart Bio, a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, announced the pricing of its upsized initial public offering of 21,250,000 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds from the initial public offering, before deducting underwriting discounts and commissions and other offering expenses payable by Braveheart Bio, are expected to be $382.5 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. Wilson Sonsini Goodrich & Rosati advised Braveheart Bio on patent matters related to the transaction.
Client Highlights
7.08.26
Wilson Sonsini Advises Crinetics on Patent Matters Related to $10 Billion Acquisition by Vertex
On July 6, 2026, Vertex Pharmaceuticals and Crinetics Pharmaceuticals, a global pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases, announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10 billion, or approximately $8.8 billion net of estimated cash acquired. Wilson Sonsini Goodrich & Rosati is patent counsel to Crinetics and advised the company on patent matters related to the transaction.
Client Highlights
5.11.26
Wilson Sonsini Advises Odyssey Therapeutics on Patent Matters Related to IPO
On May 7, 2026, Odyssey Therapeutics, a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Odyssey’s common stock began trading on the Nasdaq Capital Market on May 8, 2026, under the ticker symbol “ODTX.” The offering closed on May 11, 2026. Wilson Sonsini Goodrich & Rosati advised Odyssey on patent matters related to the transaction.
Client Highlights
1.12.26
Wilson Sonsini Advises Crinetics on Patent Matters Related to Public Offering
On January 6, 2026, Crinetics Pharmaceuticals, a pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced the pricing of an underwritten public offering of 7,620,000 shares of its common stock at a price to the public of $45.95 per share. All of the shares to be sold in the offering are to be sold by Crinetics, and the gross proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $350 million. Wilson Sonsini Goodrich & Rosati advised Crinetics on patent matters related to the public offering.
Client Highlights
12.03.25
Wilson Sonsini Advises Solve Therapeutics on Patent Matters Related to $120 Million Financing
On November 17, 2025, Solve Therapeutics, a clinical-stage biotechnology company developing best-in-class antibody-drug conjugates (ADCs) for solid tumor malignancies, announced it raised $120 million in an oversubscribed and upsized financing to accelerate the development of its clinical pipeline and proprietary CloakLink™ linker platform. This latest funding follows a $75 million financing completed in December 2024, bringing Solve’s total capital raised to $321 million. Wilson Sonsini Goodrich & Rosati advised Solve Therapeutics on patent matters related to the transaction.
Client Highlights
10.17.25
Wilson Sonsini Advises SR One on Veradermics' Oversubscribed Series C
On October 15, 2025, Veradermics, a dermatologist-founded, late clinical-stage biopharmaceutical company developing therapeutics for common dermatologic conditions, announced the completion of an oversubscribed $150 million Series C financing. SR One led the funding round, with participation from new investors Viking Global Investors, Marshall Wace, Invus, funds managed by abrdn Inc., Columbia Threadneedle Investments, Infinitium, LifeSci Venture Partners, and current investors including Longitude Capital, Suvretta Capital Management, Surveyor Capital, and other undisclosed investors. Wilson Sonsini Goodrich & Rosati advised lead investor SR One on the transaction.
Client Highlights
4.07.25
Wilson Sonsini Advises RayThera on $110 Million Series A
On April 4, 2025, San Diego-based RayThera, Inc., a biotechnology company focused on small molecule therapies in immunology, announced the successful completion of a $110 million Series A round co-led by Foresite Capital and OrbiMed Advisors, with participation from TTM Capital. Wilson Sonsini Goodrich & Rosati advised RayThera on the transaction.
Client Highlights
3.17.25
Wilson Sonsini Advises Vivace on Patent Matters related to $35 Million Series D
On March 12, 2025, Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, announced the closing of a $35 million Series D financing. The round was led by RA Capital Management, an existing investor, and included investment from other existing investors Canaan Partners and Cenova Capital. Wilson Sonsini Goodrich & Rosati advised Vivace on patent matters related to the transaction.
Proceeds from the financing will support the continued clinical development of the company's first-in-class and best-in-class transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, with an initial focus on mesothelioma.
Proceeds from the financing will support the continued clinical development of the company's first-in-class and best-in-class transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, with an initial focus on mesothelioma.
Client Highlights
10.15.24
Wilson Sonsini Advises Crinetics Pharmaceuticals on Patent Matters Related to Upsized $500 Million Common Stock Offering
On October 8, 2024, Crinetics Pharmaceuticals, a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced the pricing of an upsized underwritten public offering of 10 million shares of its common stock at a price to the public of $50.00 per share. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $500 million. In addition, Crinetics has granted the underwriters a 30-day option to purchase up to an additional 1.5 million shares of common stock. Wilson Sonsini Goodrich & Rosati is advising Crinetics on patent matters related to the transaction.
Client Highlights
9.17.24
Wilson Sonsini Advises MBX Biosciences on Patents Matters Related to IPO
On September 16, 2024, MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, announced the closing of its upsized initial public offering. The aggregate gross proceeds from the offering were approximately $187.7 million, before deducting underwriting discounts and commissions and offering expenses. Wilson Sonsini Goodrich & Rosati advised MBX Biosciences on patent matters related to the upsized IPO.
Client Highlights
8.19.24
Firm Advises Avidity Biosciences on IP Matters Related to Public Offering
On August 19, 2024, Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced that it has closed its previously announced underwritten public offering of 8,418,000 shares of its common stock, including 1,098,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $41.00 per share. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $345.1 million. Wilson Sonsini Goodrich & Rosati is patent counsel to Avidity and represented the company in IP matters related to this transaction.